Ascendis Pharma A/S (ASND) Q3 2019 Earnings Conference Call November 15, 2019 4:30 PM ET
Company Participants
Scott Smith - SVP and CFO
Jan Mikkelsen - President and CEO
Juha Punnonen - Head of Oncology
Dana Pizzuti - Head of Development Operations
Conference Call Participants
Jessica Fye - JP Morgan
Alethia Young - Cantor Fitzgerald
Tazeen Ahmad - Bank of America Merrill Lynch
David Lebowitz - Morgan Stanley
Michelle Gilson - Canaccord
Liana Moussatos - Wedbush Securities
Josh Schimmer - Evercore ISI
Joseph Schwartz - SVB Leerink
Adam Walsh - Stifel
Nick Abbott - Wells Fargo Securities
Operator
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Third Quarter 2019 Ascendis Pharma Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers presentation there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded. [Operator Instructions]
Now, I would now like to hand the conference over to our Senior Vice President and Chief Financial Officer, Mr. Scott Smith.
Scott Smith
Thank you, operator. Thank you, everyone, for joining our third quarter 2019 financial results conference call today. I'm Scott Smith, Chief Financial Officer of Ascendis. Joining me on today's call is Jan Mikkelsen, President and Chief Executive Officer; Tom Larson, Chief Commercial Officer; Juha Punnonen, Head of Oncology and Dr. Dana Pizzuti, Head of Development Operations.
Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include that are not limited to our progress on our pipeline candidates and our expectations with respect to their continued progress, statements regarding our strategic plans, our goals regarding our clinical
- Read more current ASND analysis and news
- View all earnings call transcripts